|Day Low/High||575.12 / 582.72|
|52 Wk Low/High||301.79 / 664.64|
Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.
The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.
I know that Trump's going to blunt our community mask initiative because who needs masks if it isn't a big deal if you are sick?
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
The RMPIA rose 13.8% during the quarter, leaving it up just shy of 29% on a year-to-date basis, thanks to performance by CRM, AAPL , NKE and TMO.
It's remarkable to see such excitement based on totally contradictory theories and themes.
The charts of REGN could use more than media coverage.
This is what's known as a positioning week, and starting Monday you're going to hear a ton of things.
Neither candidate seems to be the enemy of the market -- at least not yet.
I would not view what appears to be an increasingly likely Democratic victory as a reason to sell stocks.
* The 2016 Presidential election provided the contrary - a Trump win and an advancing stock market * The 2020 Presidential election may provide another contrary - a Biden win and an advancing market * President Trump's path to victory is narrowing *...
Markets now look to Treasury Secretary Mnuchin and Speaker Pelosi to do something.
"Just one more thing." -- Lt. Columbo The positive Regeneron antibody cocktail news underscores something that I planned to discuss in my opener tomorrow (Is This The Biden Bump?) Specifically, the market has already completed a consolidation phase ...
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
Do these shares get back to the 2020 highs that were reached back in January?
Should the economy see some organic growth, this stock can run as high as $220.
Markets may believe that we are closer to the effective use of vaccines and therapeutics than we know in this battle against Covid-19.
Wendy's, Regeneron and Teladoc -- why would you unload them now?
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
Ask yourself: Would you pay a higher multiple for the company that puts together a successful cocktail for Covid-19?
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
Our fate is in the hands of a few dozen companies with a dizzying array of clinical trials, and whoever gets there first is gonna make a fortune.
Let's take a close look at Gilead Sciences, Regeneron and Eli Lilly.
This is how you can tell which camp is winning and which is losing in this time of Covid-contradiction.
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.